BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 38138214)

  • 21. Integrated multi-omics analysis identifies CD73 as a prognostic biomarker and immunotherapy response predictor in head and neck squamous cell carcinoma.
    Shen A; Ye Y; Chen F; Xu Y; Zhang Z; Zhao Q; Zeng ZL
    Front Immunol; 2022; 13():969034. PubMed ID: 36466881
    [TBL] [Abstract][Full Text] [Related]  

  • 22. DNA methylation profiles differ in responders versus non-responders to anti-PD-1 immune checkpoint inhibitors in patients with advanced and metastatic head and neck squamous cell carcinoma.
    Starzer AM; Heller G; Tomasich E; Melchardt T; Feldmann K; Hatziioannou T; Traint S; Minichsdorfer C; Schwarz-Nemec U; Nackenhorst M; Müllauer L; Preusser M; Berghoff AS; Fuereder T
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35338086
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The current advances and future directions of PD-1/PD-L1 blockade in head and neck squamous cell carcinoma (HNSCC) in the era of immunotherapy.
    Chen Y; Ding X; Bai X; Zhou Z; Liu Y; Zhang X; Yu J; Hu M
    Int Immunopharmacol; 2023 Jul; 120():110329. PubMed ID: 37207445
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness and safety of weekly paclitaxel and cetuximab as a salvage chemotherapy following immune checkpoint inhibitors for recurrent or metastatic head and neck squamous cell carcinoma: A multicenter clinical study.
    Wakasaki T; Manako T; Yasumatsu R; Hara H; Toh S; Masuda M; Yamauchi M; Kuratomi Y; Nishimura E; Takeuchi T; Matsuo M; Jiromaru R; Hashimoto K; Komune N; Nakagawa T
    PLoS One; 2022; 17(7):e0271907. PubMed ID: 35901098
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differences in patterns of survival in metastatic adenoid cystic carcinoma of the head and neck.
    van Weert S; Reinhard R; Bloemena E; Buter J; Witte BI; Vergeer MR; Leemans CR
    Head Neck; 2017 Mar; 39(3):456-463. PubMed ID: 27775851
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of cetuximab-containing regimens in the treatment of recurrent/metastatic head and neck cancer after progression to immune checkpoint inhibitors.
    Lai CL; Chen TH; Chang PM; Tai SK; Chu PY; Yang MH
    J Chin Med Assoc; 2022 Jun; 85(6):687-692. PubMed ID: 35507025
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinicopathologic implications of Myb and Beta-catenin expression in adenoid cystic carcinoma.
    Park S; Vora M; van Zante A; Humtsoe J; Kim HS; Yom S; Agarwal S; Ha P
    J Otolaryngol Head Neck Surg; 2020 Jul; 49(1):48. PubMed ID: 32650834
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumor growth rate as a prognostic factor for metastatic or recurrent adenoid cystic carcinoma of the head and neck patients treated with carboplatin plus paclitaxel.
    Fukuda N; Fujiwara Y; Wang X; Ohmoto A; Urasaki T; Hayashi N; Sato Y; Nakano K; Yunokawa M; Ono M; Tomomatsu J; Takahashi S
    Eur Arch Otorhinolaryngol; 2021 Aug; 278(8):3037-3043. PubMed ID: 33219858
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Emerging immune checkpoint inhibitors for the treatment of head and neck cancers.
    Green SE; McCusker MG; Mehra R
    Expert Opin Emerg Drugs; 2020 Dec; 25(4):501-514. PubMed ID: 33196319
    [No Abstract]   [Full Text] [Related]  

  • 30. Exploring long-term responses to immune checkpoint inhibitors in recurrent and metastatic head and neck squamous cell carcinoma.
    Bila M; Franken A; Van Dessel J; Garip M; Meulemans J; Willaert R; Hoeben A; Vander Poorten V; Clement PM
    Oral Oncol; 2024 Feb; 149():106664. PubMed ID: 38113661
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
    Suzuki S; Toyoma S; Kawasaki Y; Koizumi K; Iikawa N; Shiina K; Endo T; Abe T; Kouga T; Yamada T
    Medicina (Kaunas); 2021 Oct; 57(11):. PubMed ID: 34833369
    [No Abstract]   [Full Text] [Related]  

  • 32. Hyperprogressive disease and its clinical impact in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with immune-checkpoint inhibitors: Korean cancer study group HN 18-12.
    Park JH; Chun SH; Lee YG; Chang H; Lee KW; Kim HR; Shin SH; An HJ; Lee KE; Hwang IG; Ahn MJ; Kim SB; Keam B
    J Cancer Res Clin Oncol; 2020 Dec; 146(12):3359-3369. PubMed ID: 32671504
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chemotherapy after immune checkpoint blockade in patients with recurrent, metastatic squamous cell carcinoma of the head and neck.
    Kacew AJ; Harris EJ; Lorch JH; Schoenfeld JD; Margalit DN; Kass JI; Tishler RB; Haddad RI; Hanna GJ
    Oral Oncol; 2020 Jun; 105():104676. PubMed ID: 32251982
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A systematic review and meta-analysis of prognostic indicators in patients with head and neck malignancy treated with immune checkpoint inhibitors.
    Kang D; Liu S; Yuan X; Liu S; Zhang Z; He Z; Yin X; Mao H
    J Cancer Res Clin Oncol; 2023 Dec; 149(20):18215-18240. PubMed ID: 38078963
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interference of tumour mutational burden with outcome of patients with head and neck cancer treated with definitive chemoradiation: a multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group.
    Eder T; Hess AK; Konschak R; Stromberger C; Jöhrens K; Fleischer V; Hummel M; Balermpas P; von der Grün J; Linge A; Lohaus F; Krause M; Baumann M; Stuschke M; Zips D; Grosu AL; Abdollahi A; Debus J; Belka C; Pigorsch S; Combs SE; Budach V; Tinhofer I;
    Eur J Cancer; 2019 Jul; 116():67-76. PubMed ID: 31173964
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of immune checkpoint inhibitors in recurrent or metastatic head and neck squamous cell carcinoma: A systematic review and meta-analysis of randomized clinical trials.
    Dang S; Zhang S; Zhao J; Li X; Li W
    Cancer Med; 2023 Oct; 12(20):20277-20286. PubMed ID: 37814950
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dominant cell type analysis predicts head and neck adenoid cystic carcinoma outcomes.
    Xuan L; Yuan J; Zhang H; Zhang Y; Liu H
    Ann Diagn Pathol; 2022 Feb; 56():151867. PubMed ID: 34826781
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comprehensive molecular characterization of adenoid cystic carcinoma reveals tumor suppressors as novel drivers and prognostic biomarkers.
    Persson M; Andersson MK; Sahlin PE; Mitani Y; Brandwein-Weber MS; Frierson HF; Moskaluk C; Fonseca I; Ferrarotto R; Boecker W; Loening T; El-Naggar AK; Stenman G
    J Pathol; 2023 Nov; 261(3):256-268. PubMed ID: 37565350
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Survival Analysis of 76 Cases of Head and Neck Adenoid Cystic Carcinoma
with Lung Metastasis].
    Yu Z; Yu L; Chen X; Yang X; Zhang B; Yu T; Du X
    Zhongguo Fei Ai Za Zhi; 2021 Jun; 24(6):412-419. PubMed ID: 34157801
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nivolumab for Platinum-refractory and -sensitive Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma.
    Okada T; Matsuki T; Fushimi C; Okamoto I; Sato H; Kondo T; Tokashiki K; Ito T; Masubuchi T; Tada Y; Miura K; Hanyu K; Omura GO; Takahashi H; Yamashita T; Oridate N; Tsukahara K
    Anticancer Res; 2022 Oct; 42(10):4907-4912. PubMed ID: 36192003
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.